AstraZeneca today announced that its Chief Executive David Brennan will receive no increase to his base salary this year, as the drug maker continues a freeze for top executives imposed last year due to weak economic conditions.
Brennan's 2010 salary will remain at $1.4 million, the same level since 2008. However, Brennan’s overall compensation has been on the rise for the past few years. His total remuneration, which includes bonus, shares and other items, rose 5% to $4.9 million for 2009, versus $4.7 million for 2008, according to documents recently filed with the Securities and Exchange Commission.
AstraZeneca said the base-salary freeze for 2010 also applies to other senior executives whose responsibilities are unchanged.
While it is laudable that the company is freezing the base salary of its executives, most of their annual compensation is derived from bonuses, stock grants and options and other perks and benefits. I am certain that the hundreds of thousands of pharmaceutical employees who lost their jobs over the past three years can sleep better at night knowing that pharmaceutical executives are finally feeling the pain and sharing the pain of a down economy.
Hat tip to Ed at Pharmalot!
Until next time…
Good Luck and Good Job Hunting!!!!!!!!!!